Tan K S, McFarlane L C, Lipworth B J
Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Scotland, United Kingdom.
Chest. 1998 Feb;113(2):278-82. doi: 10.1378/chest.113.2.278.
Previously it has been shown that there is abnormal hormonal control of beta2-adrenoceptors in asthmatic women. Exogenous progesterone but not estradiol produces paradoxic downregulation and desensitization of beta2-adrenoceptors in asthmatic women when compared with nonasthmatic subjects. This study investigates the effect of the oral combined contraceptive pill (OCP) on beta2-adrenoceptor regulation and function in female asthmatic patients.
The study population was comprised of 11 women with stable mild to moderate asthma. The mean age was 25 years; the FEV1 was 89% of predicted, and the forced expiratory flow, mid-expiratory phase (FEF25-75%) was 69% of predicted.
Patients were evaluated while on (day 20 to 21) and off (day 5 to 7) the OCP during a 28-day calendar period.
Serum sex hormones, lymphocyte beta2-adrenoceptor parameters, and bronchodilator and systemic dose-response curves (DRCs) to albuterol (Salbutamol) (100 to 1,600 microg) were measured at both on and off periods.
Serum levels of endogenous estradiol and progesterone were both suppressed by the OCP. Baseline FEV1 were not different while patients were on (2.70 L) and off (2.72 L) the OCP. There were no significant differences in lymphocyte beta2-adrenoceptor parameters between the two phases of the cycle. Receptor density (geometric mean Bmax) was 1.78 (on OCP) vs 1.86 (off OCP) fentomole/10(6) cells, maximal cyclic adenosine monophosphate response to isoprenaline was 6.60 (on OCP) vs 7.58 (off OCP) pmol/10(6) cells, and binding affinity was 14.0 (on OCP) and 13.6 (off OCP) pmol/L. Likewise, there were no significant differences in the bronchodilator and systemic DRCs constructed at both phases of the cycle as evaluated: area-under-curve (AUC) FEV1 was 0.53 (on OCP) vs 0.56 (off OCP) L.h; and AUC FEF25-75% was 3,130 (on OCP) vs 3,640 (off OCP) L. Potassium (K) and finger tremor responses were unaltered between the two periods: AUC K was 0.50 (on OCP) vs 0.44 (off OCP) mmol . h/L and AUC tremor was 0.72 (on OCP) vs 0.89 (off OCP) log units.h.
The OCP did not alter beta2-adrenoceptor regulation and function in stable female asthmatic patients. Further studies are required in patients who have premenstrual asthma.
此前已有研究表明,哮喘女性体内β2肾上腺素能受体存在激素控制异常。与非哮喘受试者相比,外源性孕酮而非雌二醇会使哮喘女性的β2肾上腺素能受体出现反常的下调和脱敏。本研究旨在探讨口服复方避孕药(OCP)对女性哮喘患者β2肾上腺素能受体调节及功能的影响。
研究对象为11名病情稳定的轻度至中度哮喘女性。平均年龄25岁;第一秒用力呼气容积(FEV1)为预测值的89%,呼气中期流速(FEF25 - 75%)为预测值的69%。
在28天的周期内,对患者在服用OCP期间(第20至21天)和停用OCP期间(第5至7天)进行评估。
在服用和停用OCP期间,均测量血清性激素、淋巴细胞β2肾上腺素能受体参数,以及对沙丁胺醇(100至1600微克)的支气管扩张剂和全身剂量反应曲线(DRCs)。
OCP抑制了内源性雌二醇和孕酮的血清水平。患者服用OCP时(2.70升)和停用OCP时(2.72升)的基线FEV1无差异。周期的两个阶段之间,淋巴细胞β2肾上腺素能受体参数无显著差异。受体密度(几何平均Bmax)在服用OCP时为1.78,停用OCP时为1.86飞摩尔/10⁶细胞;对异丙肾上腺素的最大环磷酸腺苷反应在服用OCP时为6.60,停用OCP时为7.58皮摩尔/10⁶细胞;结合亲和力在服用OCP时为14.0,停用OCP时为13.6皮摩尔/升。同样,在周期的两个阶段构建的支气管扩张剂和全身DRCs也无显著差异:FEV1的曲线下面积(AUC)在服用OCP时为0.53,停用OCP时为0.56升·小时;FEF25 - 75%的AUC在服用OCP时为3130,停用OCP时为3640升。两个时期之间钾(K)和手指震颤反应未改变:K的AUC在服用OCP时为0.50,停用OCP时为0.44毫摩尔·小时/升;震颤的AUC在服用OCP时为0.72,停用OCP时为0.89对数单位·小时。
OCP不会改变病情稳定的女性哮喘患者的β2肾上腺素能受体调节及功能。对于经前期哮喘患者,还需要进一步研究。